[1] 汪莉,吴焕文,宋智勇.双向调节蛋白与肿瘤的相关性研究进展. 临床与病理杂志,2016,36:71-75.
[2] Schiffer E, Housset C, Cacheux W, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology,2005,41:307-314.
[3] Berasain C, Castillo J, Prieto J, et al. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int,2007,27:174-185.
[4] Qiao Q, Zhang J, Wang W, et al. Over-expression of transforming growth factor-alpha and epidermal growth factor receptor in human hepatic cirrhosis tissues. Hepatogastroenterology,2008,55:169-172.
[5] Tsai W, Lee H, Jin J, et al.Association between osteopontin and EGFR expression with clinicopathological parameters in hepatocellular carcinoma. Chin J Physiol,2012,55:412-420.
[6] Freed DM,Bessman NJ,Kiyatkin A,et al. EGFR Ligands differentially stabilize receptor dimers to specify signaling kinetics.Cell, 2017, 17:9-17.
[7] Ciarloni L,Mallepell S,Brisken C. Amphiregulin is an essential mediator of estrogen receptor alpha function inmammary gland development. Proc Natl Acad Sci USA,2007,104: 5455-5460.
[8] Castillo J,Erroba E,Perugorria MJ,et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res, 2006, 66:6129-6138.
[9] Berasain C, Garcia-Trevijano ER, Castillo J, et al.Amphiregulin: an early trigger for liver regeneration in mice. Gastroenterology, 2005,128:424-432.
[10] Berasain C, Garcǐa-Trevijano ER, Castillo J, et al.Novel role for amphiregulin in protection from liver injury. J Biol Chem,2005,280:19012-1920.
[11] Ahn EY, Kim JS, Kim GJ, et al. RA SSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma. Mol Cancer Res, 2013, 11: 748-758.
[12] Weissferdt A, Lin H, Woods D, et al. HER family receptor and ligand status in thymic carcinoma. Lung Cancer, 2012,77:515-521,.
[13] Han SX, Bai E, Jin GH,et al. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res,2014,2014:261365.
[14] 李军,田野.以表皮生长因子受体和胰岛素样生长因子-1受体为靶点的肿瘤治疗研究. 临床和实验医学杂志,2016,15:823-825.
[15] Bellmunt J,de Wit R,Albiol S,et al. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol,2003,47:195-206.
[16] 李亚楠,周云芝,王洪武. 肺鳞癌分子靶向治疗的研究现状.中国肺癌杂志,2014,17:618-624. |
